News
PBMWW
0.0249
+19.14%
0.0040
Weekly Report: what happened at PBMWW last week (1124-1128)?
Weekly Report · 5d ago
Psyence BioMed Launches Psilocybin Longevity Research Program
Reuters · 11/25 12:11
Weekly Report: what happened at PBMWW last week (1117-1121)?
Weekly Report · 11/24 09:15
Psyence BioMed Takes Minority Stake in PsyLabs to Boost African Ibogaine Operations
Reuters · 11/21 22:18
Weekly Report: what happened at PBMWW last week (1110-1114)?
Weekly Report · 11/17 09:15
Psyence BioMed Invests in PsyLabs to Establish Ibogaine Operations in Africa
Reuters · 11/12 12:00
PSYENCE BIOMED ESTABLISHES IBOGAINE OPERATIONS IN AFRICA THROUGH STRATEGIC INVESTMENT IN PSYLABS
Reuters · 11/12 12:00
Psyence BioMed Doses Multiple Patients in Phase IIb Psilocybin Trial for Palliative Care
Reuters · 11/10 21:16
Weekly Report: what happened at PBMWW last week (1103-1107)?
Weekly Report · 11/10 09:14
Psyence BioMed Doses Multiple Patients in Phase IIb Psilocybin Trial for Adjustment Disorder
Reuters · 11/06 12:00
PSYENCE BIOMED DOSES MULTIPLE PATIENTS AND EXPANDS CLINICAL SITES IN PHASE IIB STUDY FOR ADJUSTMENT DISORDER IN PALLIATIVE CARE
Reuters · 11/06 12:00
Psyence BioMed Invests $3.5 Million in PsyLabs
Reuters · 11/03 12:00
Weekly Report: what happened at PBMWW last week (1027-1031)?
Weekly Report · 11/03 09:14
Weekly Report: what happened at PBMWW last week (1020-1024)?
Weekly Report · 10/27 09:15
Weekly Report: what happened at PBMWW last week (1013-1017)?
Weekly Report · 10/20 09:15
Weekly Report: what happened at PBMWW last week (1006-1010)?
Weekly Report · 10/13 09:15
PSYENCE BIOMEDICAL LTD: CO’S CHAIRMAN, JODY AUFRICHTIG, HAS ASSUMED ROLE OF CEO
Reuters · 10/09 20:19
PSYENCE BIOMEDICAL LTD: NEIL MARESKY HAS TRANSITIONED FROM HIS ROLE AS CEO AND DIRECTOR TO SERVE AS CO’S GLOBAL HEAD, CLINICAL DEVELOPMENT
Reuters · 10/09 20:19
Psyence Biomedical names Jody Aufrichtig as CEO as Neil Maresky transitions to lead clinical development
Reuters · 10/09 20:17
PSYENCE BIOMEDICAL: FILES PROSPECTUS RELATES TO POTENTIAL OFFER, RESALE, FROM TIME TO TIME 50 MLN COMMON SHARES BY WHITE LION CAPITAL, LLC
Reuters · 10/06 21:35
More
Webull provides a variety of real-time PBMWW stock news. You can receive the latest news about PSYENCE BIOMEDICAL LTD through multiple platforms. This information may help you make smarter investment decisions.
About PBMWW
Psyence Biomedical Ltd is a multi-asset, vertically integrated biopharmaceutical company specializing in psychedelic-based therapeutics. The Company is focused on developing nature-derived (non-synthetic) psilocybin-based psychedelic medicine. It is dedicated to addressing unmet mental health needs, particularly in palliative care. Its ongoing Phase IIb psilocybin clinical trial in Australia focuses on adjustment disorder in patients diagnosed with cancer.